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Oxidation reduction is a process which involves exchange of
electrons from a reducing agent to an oxidizing agent. The oxi-
dized and reduced species in a half reaction form a redox cou-
ple (Housecroft and Constable, 2006).
Hydralazine is an antihypertensive drug with brand names
of Apo-Hydral, Apresoline, Novo-Hylazin, Apo-Hydralazine,
etc. (Katherine, 2004; Champe and Harvey, 2000). It has anti-
oxidant activity and known for in vitro generation of reactive
species of oxygen (ROS), nitrogen (RNS) and prostaglandinm (S. Imad).
ity.
lsevier(PG) (Daiber et al., 2005; Leiro et al., 2004; Carmody and
Anderson, 2007). It is a white to off-white, odorless crystalline
powder. It is soluble in water, slightly soluble in alcohol, and
very slightly soluble in ether and melts at about 275 C, with
decomposition. It has pKa value 7.3. Its chemical name is
1-hydrazinophthalazine monohydrochloride and has the
following structure (Clark’s, 1986; Merck Index, 1997).
N
N
NH NH 2
.HCl
There are number of techniques used for the determination of
redox potential. Here we used spectrophotometeric technique
for redox study.
The redox potential of hydralazine hydrochloride was
determined by using potassium ferricyanide complex
(K3[Fe(CN)6]). This complex is colored with ferric and color-
less with ferrous. The addition of hydralazine reduced ferric
(Fe3+) into ferrous (Fe2+) and decreased the absorbance of
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Figure 1 Spectrophotometric titration of K3[(Fe(CN)6]
(0.001 M) with hydralazine hydrochloride (0.01 M) at 25 C.
242 S. Imad et al.the complex. From the change in absorbance the extent of
reduction was determined.
The concentration of reduced and oxidized species can be
calculated as follows:
½FeðIIIÞcomplexeq ¼
Absorbance
e
½FeðIIÞcomplexeq ¼ ½FeðIIIÞcomplextotal  ½FeðIIIÞcomplexeq
½Hydralazineoxidized form ¼ ½FeðIIÞeq
½Hydralazineeq ¼ ½Hydralazinetotal  ½Hydralazineoxidized
These values can be used to calculate the equilibrium con-
stant, Keq, where,
Keq ¼
½FeðIIÞeq½Hydralazineoxidized
½FeðIIIÞcomplexeq½Hydralazineeq
The equilibrium constant for oxidation–reduction equilib-
rium can be calculated from the standard cell potential of
the reaction, which in turn may be calculated from the stan-
dard electrode potential for the half reactions.
The change in standard Gibbs free energy for the reaction is
given by the equation:
G0 ¼ nFE0 ð1Þ
And DG0 is related to the equilibrium constant by the
equation
DG0 ¼ RT lnK ð2Þ
An expression that relates the equilibrium constant directly
to the cell potential is obtained by combining Eqs. (1) and (2)
(Christian, 2004; Mortimer, 1991),
E0 ¼ RT
nF
lnKeq ð3Þ
With the help of this expression formal redox potential or
redox equivalent of hydralazine can be calculated by using
the formal redox potential of Fe(III)/Fe(II) half cell in the
K3[Fe(CN)6] complex, by using the following relationship
(Robert et al., 2004):
E0cell ¼ E0oxi  E0red ð4Þ
The reduction of Fe(III)–hydralazine complex was studied
by addition of ascorbic acid.
Ascorbic acid is a mild reducing agent and a weak acid,
while the radical HA is a very strong acid. The binegative
ene-diol anion of ascorbic acid, L2, is a bidentate ligand
and is capable of reacting with metal ions Mn+ of coordina-
tion number 4 or 6 to form complexes. It is a strong two-elec-
tron reducing agent that is readily oxidized in one-electron
steps by metal ions and metal complexes in their higher valence
states. The ﬁrst step in the reaction is the formation of mono-
protonated Fe(III) complex. This short lived intermediate rap-
idly undergoes an intermolecular one-electron transfer to give
a deprotonated Fe(II) complex of the ascorbate redical anion.
The complex dissociates to a free radical anion, which may
then combine with a second ferric ion, which in turns under-
goes a second intramolecular electron transfer to give the ﬁnal
product dehydroascorbic acid (Martell, 1982).2. Materials and methods
All the chemicals used were of analytical grade, and employed
without further puriﬁcation. All the volumetric glassware used
was of standard quality. Special care was taken to wash them
thoroughly before use. For this study CO2 free water was used
which was prepared by boiling distilled deionized water for
10 min and then cooling it in airtight ﬂask (Cox, 1995).
Shimadzu spectrophotometer, model UV-160A, was used
to record spectra and for the measurement of change in absor-
bance of complex. Three types of spectrophotometric titrations
were performed in order to study the redox properties of
hydralazine. In ﬁrst set of experiment titration of potassium
ferricyanide was performed with hydralazine. The measure-
ments were taken at the kmax (420 nm) of potassium ferricya-
nide complex. 0.001 M K3[Fe(CN)6] solution and 0.01 M
hydralazine hydrochloride solutions were prepared in 0.1 M
solution of KNO3. In this titration, twelve volumetric ﬂasks
were taken and then numbered. Complex (2.0 mL) was taken
in each ﬂask. Different volumes from 0 to 15.0 ml of hydral-
azine solution were added in respective ﬂasks, and volume
was made with 0.1 M KNO3. Temperature was maintained
at 25 C by thermostat. These solutions were then subjected
to spectrophotometric analysis and change in absorbance
was noted until it became constant.
In second set of experiment reduction of potassium ferricy-
anide complex was studied by ascorbic acid following the same
procedure.
In third set of experiment Fe(III)–hydralazine complex was
treated with ascorbic acid. The experiment was repeated at pH
3.0, 5.0, 7.0 and 8.0.
3. Results and discussion
In the spectrophotometric titration of potassium ferricyanide
with hydralazine, absorbance of the potassium ferricyanide
complex decreased gradually with the addition of hydralazine
(Fig. 1). The redox equivalent of hydralazine was determined
by the data available from spectrophotometric titration. The
Table 1 Redox potential values of hydralazine hydrochloride as determined by spectrophotometric titration.
Absorbance [Fe(III)]eq [(Fe(II)]eq ½Redeq ½Red0eq Keq E0
0.904 – – – –
0.559 1.10E03 9.02E04 1.10E03 9.02E04 0.675 +0.335
0.512 1.00E03 9.95E04 1.00E03 9.95E04 0.981 +0.357
0.462 9.06E04 1.09E03 9.06E04 1.09E03 1.46 +0.380
0.427 8.38E04 1.16E03 8.38E04 1.16E03 1.92 +0.397
0.426 8.53E04 1.16E03 8.53E04 1.16E03 1.94 +0.397
0.408 8.00E04 1.00E03 8.00E04 1.00E03 2.25 +0.406
0.350 6.86E04 1.31E03 6.86E04 1.31E03 3.66 +0.435
0.315 6.18E04 1.38E03 6.18E04 1.38E03 5.01 +0.453
0.305 5.98E04 1.40E03 5.98E04 1.40E03 5.49 +0.459
0.276 2.71E04 1.45E03 2.71E04 1.45E03 29.07 +0.557
0.221 1.88E04 2.45E03 1.88E04 2.45E03 13.07 +0.519
Average = +0.469 V
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Figure 3 Effect of pH on Fe(II)–hydralazine complex (1:7 ML
ratio).
A study of redox properties of hydralazine hydrochloride, an antihypertensive drug 243formal redox potential of potassium ferricyanide is +0.358 V
(Dean, 1973).
By means of the data obtained the concentration of com-
plex and other species was deduced and the equilibrium con-
stant (Keq) was calculated. E
0
cell was calculated using Eq. (3).
E0red of the complex was calculated using Eq. (4).
The formal redox potential of Hydralazine was found to be
+0.469 V (Table 1).
Titration of potassium ferricyanide complex with ascorbic
acid was performed in order to compare both hydralazine
and ascorbic acid (Fig. 2).
The addition of hydralazine in potassium ferricyanide com-
plex causes a decrease in absorbance. Decrease in the absor-
bance of the complex is faster in case of ascorbic acid as
compared to hydralazine (Figs. 1 and 2). It shows that ascorbic
acid is good reducing agent than hydralazine.
Titration of hydralazine with ascorbic acid was performed
at pH 3.0, 5.0, 7.0 and 8.0. Before studying the redox proper-
ties at different pH Fe(II)–hydralazine and Fe(III)–hydralazine
complexes were prepared in solutions of different pH and
scanned (Figs. 3 and 4). Spectra of both at pH 3 show that
the formation of Fe(II)–hydralazine is very slow at pH 3.0,
while it increases at pH 4.0 and above. Formation of
Fe(III)–hydralazine is fast at pH 3.0 (Fig. 5).0
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Figure 2 Spectrophotometric titration of K3[(Fe(CN)6]
(0.001 M) with ascorbic acid (0.01 M) at 25 C.The data obtained from the addition of ascorbic acid in
Fe(III)–hydralazine complex at different pH shows that de-
crease in the absorbance of Fe(III)–hydralazine complex slows
down on increasing pH. As Fe(II)–hydralazine complex for-0
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Figure 4 Effect of pH on Fe(III)–hydralazine complex (1:7 ML
ratio).
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Figure 5 Spectra of Fe(II)–hydralazine and Fe(III)–hydralazine
at pH 3.0 after 30 min.
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Figure 6 Spectrophotometric titration of Fe(III)–hydralazine
complex by ascorbic acid at pH 3.0.
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Figure 7 Spectrophotometric titration of Fe(III)–hydralazine
complex by ascorbic acid at pH 5.0.
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Figure 9 Spectrophotometric titration of Fe(III)–hydralazine
complex by ascorbic acid at pH 8.0.
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Figure 8 Spectrophotometric titration of Fe(III)–hydralazine
complex by ascorbic acid at pH 7.0.
244 S. Imad et al.mation starts near pH 4.0. So at pH 3.0 Fe(III)–hydralazine
complex contains most of the oxidized form of Fe(III), which
can be easily reduced. So at pH 3.0 ascorbic acid is undergoingtwo types of reactions, i.e., reduction as well as substitution
(Fig. 6). At pH 5.0 most of the Fe(III) in the complex is re-
duced to Fe(II) by hydralazine. As at pH 5.0 the rate of forma-
tion of Fe(II)–hydralazine is faster as compared to pH 3.0
(Fig. 3). That is why substitution of hydralazine by ascorbic
acid slows down as the pH increases (Fig. 7). The same was ob-
served even at higher pH (Figs. 8 and 9). The reduction study
with ascorbic acid shows that at lower pH values Fe(III)–
hydralazine complex exists in good amount and ascorbic acid
undergoing two reactions, reduction and substitution. While at
high pH values ascorbic acid is involved only in substitution
reaction.
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